NPS Pharmaceuticals, Inc. (NPS) is a clinical-stage biopharmaceutical company. The Company is focused on the development of orphan products for patients with rare gastrointestinal and endocrine disorders and high unmet medical needs. NPS clinical programs involve two therapeutic peptides to restore or replace biological function: Gattex (teduglutide) and Natpara. Teduglude, its analog of GLP-2, a protein involved in the regeneration and repair of the intestinal lining. The Company has been developing Gattex for the treatment of adults with short bowel syndrome (SBS). Natpara is the recombinant full-length human parathyroid hormone (rhPTH (1-84)), which is developing as a hormone replacement therapy for hypoparathyroidism, a rare hormone deficiency disorder, in which patients are physiologically unable to regulate the levels of calcium and phosphates in their blood due to insufficient levels of endogenous parathyroid hormone (PTH).